Becton, Dickinson and Company (BDX) Shares Sold by Taurus Asset Management LLC

Taurus Asset Management LLC lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 1.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 86,405 shares of the medical instruments supplier’s stock after selling 1,000 shares during the period. Becton, Dickinson and makes up approximately 2.6% of Taurus Asset Management LLC’s holdings, making the stock its 9th largest position. Taurus Asset Management LLC’s holdings in Becton, Dickinson and were worth $16,931,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Almanack Investment Partners LLC. purchased a new position in shares of Becton, Dickinson and during the 1st quarter worth $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in shares of Becton, Dickinson and by 55.8% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after acquiring an additional 240 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Becton, Dickinson and by 8.1% during the 2nd quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock worth $133,000 after acquiring an additional 51 shares during the last quarter. Harfst & Associates Inc. boosted its stake in shares of Becton, Dickinson and by 46.4% during the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after acquiring an additional 221 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd boosted its stake in shares of Becton, Dickinson and by 82.8% during the 2nd quarter. Harvest Fund Management Co. Ltd now owns 746 shares of the medical instruments supplier’s stock worth $146,000 after acquiring an additional 338 shares during the last quarter. 88.46% of the stock is owned by institutional investors and hedge funds.

BDX has been the topic of a number of analyst reports. Royal Bank Of Canada restated a “hold” rating and set a $210.00 target price on shares of Becton, Dickinson and in a research note on Wednesday, October 25th. Zacks Investment Research cut shares of Becton, Dickinson and from a “hold” rating to a “sell” rating in a research note on Monday, October 9th. Stifel Nicolaus restated a “buy” rating and set a $245.00 target price on shares of Becton, Dickinson and in a research note on Friday, November 3rd. Morgan Stanley lifted their target price on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research note on Friday, November 3rd. Finally, Wells Fargo & Company restated a “positive” rating and set a $235.00 target price (up previously from $225.00) on shares of Becton, Dickinson and in a research note on Tuesday, October 24th. They noted that the move was a valuation call. Four investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Becton, Dickinson and currently has a consensus rating of “Buy” and a consensus price target of $217.08.

In related news, insider Gary M. Cohen sold 15,512 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the transaction, the insider now directly owns 95,781 shares in the company, valued at approximately $19,517,294.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stephen Sichak sold 11,787 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the transaction, the insider now owns 14,038 shares in the company, valued at $2,814,057.48. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at $218.92 on Thursday. Becton, Dickinson and Company has a fifty-two week low of $161.29 and a fifty-two week high of $229.68. The company has a quick ratio of 5.03, a current ratio of 5.58 and a debt-to-equity ratio of 1.44. The firm has a market cap of $49,943.21, a PE ratio of 23.08, a PEG ratio of 1.72 and a beta of 1.07.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping analysts’ consensus estimates of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The firm had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. During the same period in the previous year, the firm posted $2.12 EPS. The business’s quarterly revenue was down 2.0% on a year-over-year basis. research analysts anticipate that Becton, Dickinson and Company will post 10.63 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be issued a $0.75 dividend. The ex-dividend date is Thursday, December 7th. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.37%. Becton, Dickinson and’s payout ratio is 62.80%.

COPYRIGHT VIOLATION NOTICE: “Becton, Dickinson and Company (BDX) Shares Sold by Taurus Asset Management LLC” was first posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.thestockobserver.com/2017/12/07/becton-dickinson-and-company-bdx-shares-sold-by-taurus-asset-management-llc.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply